Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. has partnered with Royal Columbian Hospital to test its Steriwave technology in ICUs, aiming to reduce infections and healthcare costs. The $855,000 study, backed by the hospital’s foundation, will explore Steriwave’s effectiveness in preventing ICU infections, potentially impacting patient outcomes and mortality rates. With the global ICU market in view, the collaboration could signal a significant advancement in infection control within critical care.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
